Overview

This trial has been completed.

Condition substance-related disorders
Treatment counseling
Phase phase 4
Sponsor National Institute on Drug Abuse (NIDA)
Start date April 1996
Trial size 90 participants
Trial identifier NCT00000343, NIDA-3-0010-8, Y01-3-0010-8

Summary

The purpose of this study is to identify the neurophysiologic indicators of cocaine or methamphetamine use and withdrawal, to examine the relationship between subjects' reports of depression, craving, and stimulant use, and neurophysiologic measures, and to identify neurophysiologic measures which can be used to identify new treatments for stimulant dependence.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Primary purpose treatment

Eligibility Criteria

All participants from 21 years up to 50 years old.

Inclusion Criteria

    Exclusion Criteria

      Additional Information

      Official title Brain Changes in Stimulant Dependent Subjects
      Principal investigator Walter Ling, M.D.
      Description By Incorporating QEEG into clinical trails, the plan is to develop physiologic markers of treatment efficacy, and to aid in the identification of effective treatments.
      Trial information was received from ClinicalTrials.gov and was last updated in January 2017.
      Information provided to ClinicalTrials.gov by National Institute on Drug Abuse (NIDA).